|
市場調查報告書
神經疾病之產品線：策略性回顧
The Neurology Pipeline: A Strategic Review
|
神經疾病之產品線：策略性回顧 是由出版商Decision Resources, Inc.在2009年08月所出版的。
這份英文市場調查報告書包含39 Pages 價格從美金3450起跳。
本報告為，神經疾病之產品線，並匯整GlaxoSmithKline、Roche、Eli Lilly之3大企業開發趨勢以及市場機會與今後展望，以下列摘要形式闡述。
實施概要
簡介
神經疾病產品線
- 藥劑
- 企業
- GlaxoSmithKline
- Roche
- Eli Lilly
神經疾病產品線之機會
- 有效之神經保護劑將具劃時代潛在性
- 更方便／安全之神經疾病治療藥物處方
市場統計與今後展望
表
- 神經疾病之細節
- 一般用於治療神經疾病之藥劑等級 GlaxoSmithKline之神經疾病產品線
- Roche之神經疾病產品線
- Eli Lilly之神經疾病產品線
- 神經疾病產品線之後期神經保護劑
- 2008年主要之藥劑銷售
- 2008年銷售別之主要企業
- 2008∼2013年神經疾病治療藥品之專利失效
- 2015年銷售別之主要企業
- 2015年主要神經疾病治療藥品之銷售預測
圖
- 疾病別之神經疾病產品線
- 神經疾病產品線：新進化合物之重新處方
- 神經疾病產品線：處方別藥劑
- 神經疾病產品線：藥劑標的別
- 神經疾病產品線：開發階段別
- 神經疾病產品線：企業別
- 階段別藥劑數
- 疾病別藥劑數
- 企業規模別之開發活動
- GlaxoSmithKline之加盟銷售：2008年、2015年
- 地區別市場擴大：2004∼2015年
- 等級別銷售：2008年、2015年
Abstract
Introduction
Mega-blockbuster status would be quick and sure for any safe, effective agent
that prevents the death and damage of neurons associated with
neurodegenerative diseases. The potential of such a neuroprotectant is one of
the motivations for the 188 companies currently involved in the development of
263 neurological pipeline agents, despite the plethora of marketed agents for
these diseases and disorders. Meanwhile, less-debilitating neurological
disorders that nonetheless affect patients' quality of life (e.g., migraine,
insomnia) also face significant unmet needs. Today' s pipeline of new
molecular entities (NMEs) and reformulations holds a range of agents with
potential to improve treatment and infl uence market dynamics, as well as
drive market growth through 2015.
Questions Answered in This Report
- The neurology market experienced steady growth from 2004 through 2008.
Which drug classes contributed most to this increase in sales? Which drug
classes are projected to contribute to an increase or decrease in future
sales?
- Clinical trial design and end points are a significant constraint on drug
development and market growth in the neurology indication. Which neurology
indications are particularly affected by these constraints? What specific
effects do these constraints have on the market?
- The development of a safe, efficacious neuroprotectant is the elusive
“holy grail” in the neurology market. Why is the development of
a neuroprotectant so tantalizing to the neurology field? What barriers have
prevented the development and launch of a successful neuroprotectant? Which
companies have latestage neuroprotectants in the pipeline?
- The neurology market is significant in terms of sales and is projected to
continue growing in the near future. Which companies are the current market
leaders, and which companies are projected to be the market leaders in 2015?
Which companies are attempting to enter, grow, or protect their position in
this market? Which indications will drive the majority of the growth?
Scope
- The neurology pipeline: Number of agents in development; disease
focus; NMEs versus reformulations; formulations by disease; drug targets;
phase analysis; development by company type; number of agents by phase; number
of agents by disease; profiles of GlaxoSmithKline, Roche, and Eli Lilly.
- Historical and projected neurology sales: 2004-2015 sales; leading
drug classes; current and projected market-leading companies; key patent
expiries impacting neurology sales; R&D spend of market-leading companies.
- Market opportunities/drivers: Room for an effective
neuroprotectant; new formulations/delivery systems; an aging population.
- Market constraints: Clinical trial end points; time to treatment
versus disease progression; generics.
Companies Mentioned in This Report
- Abbott Laboratories
- Aguettant
- Alliance Pharma
- Almirall
- Amgen
- Aspreva
- Astellas Pharma
- AstraZeneca
- Banyu Seiyaku
- Baxter International
- Bayer Schering
- Biofutura
- Biogen Idec
- Boehringer Ingelheim
- Bracco
- Bristol-Myers Squibb
- Britannia Pharmaceuticals
- Cambridge Labs
- Cephalon
- Chiesi
- Chugai Seiyaku
- Daiichi Sankyo
- Dainippon Sumitomo
- Dava Pharmaceuticals
- Desma
- DuPont Pharma
- Eisai
- Eli Lilly
- Endo Pharmaceuticals
- Esteve
- Forest Laboratories
- Genentech
- GlaxoSmithKline
- Grupo Ferrer
- Grupo Grunenthal
- Impax Laboratories
- Janssen
- Johnson & Johnson
- King Pharmaceuticals
- Kyowa Hakko Kirin
- Lundbeck
- Meda
- Menarini
- Merck & Co.
- Merck Serono
- Merz
- Mitsubishi Tanabe Pharma
- Novartis
- Onko
- Organon
- Orion
- Orphan Europe
- Ortho-McNeil Neurologics
- Par Pharma
- Pfizer
- Prometheus Laboratories
- Roche
- Sanofi-Aventis
- Schwartz Pharma
- Sepracor
- Shire Pharmaceuticals
- Solvay
- Takeda
- Teofarma
- Teva
- UCB
- Valeant Pharma
- Vernalis
- Wyeth
Major Neurological Diseases Mentioned in This Report
- Alzheimer' s disease (AD)
- Amyotrophic lateral sclerosis (ALS)
- Epilepsy
- Huntington' s disease (HD)
- Insomnia
- Migraine
- Multiple sclerosis (MS)
- Parkinson' s disease (PD)
- Restless legs syndrome (RLS)
- Stroke
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- The Neurological Disease Pipeline
- Agents
- Companies
- GlaxoSmithKline
- Roche
- Eli Lilly
- Opportunities in the Neurology Pipeline
- Great Potential for an Effective Neuroprotectant
- More-Convenient/Safer Formulations of Neurology Drugs
- Market Statistics and Market Outlook
- Market Statistics
- Market Drivers and Constraints
Tables
- 1. Descriptions of Neurological Disorders
- 2. Drug Classes Commonly Used to Treat Neurological Disorders
- 3. 2008 Overall R&D Spend of Companies with Leading Neurological Pipelines
- 4. GlaxoSmithKline' s Neurology Pipeline
- 5. Roche' s Neurology Pipeline
- 6. Eli Lilly' s Neurology Pipeline
- 7. Late-Stage Neuroprotectants in the Neurology Pipeline
- 8. 2008 Worldwide Sales of Leading Neurological Drugs
- 9. 2008 Market-Leading Companies, by Neurology Sales
- 10. Patent Expiries of Key Neurology Drugs, 2008-2013
- 11. 2015 Market-Leading Companies, by Estimated Neurology Sales
- 12. 2015 Estimated Worldwide Sales of Leading Neurology Drugs
Figures
- 1. Neurology Pipeline, by Disease
- 2. Neurology Pipeline: NMEs Versus Reformulations
- 3. Neurology Pipeline Agents, by Formulation
- 4. Neurology Pipeline, by Drug Target
- 5. Neurology Pipeline, by Development Phase
- 6. Neurology Pipeline, by Company
- 7. Leading Neurology Pipelines, Number of Agents by Phase
- 8. Leading Neurology Pipelines, Number of Agents by Disease
- 9. Neurology Pipeline, Development Activity by Company Size
- 10. GlaxoSmithKline Neurology Franchise Sales, 2008 and 2015
- 11. Worldwide Neurology Disease Market Growth, 2004-2015
- 12. Neurology Disease Market Growth, by Region, 2004-2015
- 13. Worldwide Sales of Neurology Drug Classes, 2008 and 2015
|
